Latest Breaking News On - Institute of the national institutes health - Page 1 : comparemela.com

ABMRF Invests in Amygdala Neurosciences to Develop ANS-858 for Alcohol Use Disorder

ANS-858 is a new selective, reversible, orally bioavailable ALDH2 Inhibitor in pre-clinical development to reduce craving.

United statesBrent blackburnBruce amblerFoundation for alcohol researchInstitute of the national institutes healthAmygdala neurosciences incNeurosciences incBoard of trusteesNational institute on alcohol abuseUs centers for diseaseGilead sciencesAlcohol beverage medicines research foundationAlcohol researchNorth americaChair boardDisease control

ABMRF Invests in Amygdala Neurosciences to Develop ANS-858 for Alcohol Use Disorder

ABMRF Invests in Amygdala Neurosciences to Develop ANS-858 for Alcohol Use Disorder
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesBruce amblerBrent blackburnBoard of trusteesAlcohol beverage medicines research foundationNational institute on alcohol abuseNeurosciences incInstitute of the national institutes healthAmygdala neurosciences incUs centers for diseaseFoundation for alcohol researchGilead sciencesAlcohol researchNorth americaChair boardDisease control

Readout of HHS Secretary Xavier Becerra s Remarks at the Sickle Cell Disease Trailblazers Event

Readout of HHS Secretary Xavier Becerra s Remarks at the Sickle Cell Disease Trailblazers Event
hhs.gov - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from hhs.gov Daily Mail and Mail on Sunday newspapers.

United statesJames eckmanJulie panepintoClarice reidRachel levineDannyk davisLos angelesDonnell ivyXavier becerraAssociation for black cardiologists incHuman servicesHealth education coordinatorNational minority health monthSickle cell disease association of americaServices administrationInstitute of the national institutes health

Inhibikase Therapeutics (IKT) Issues Letter to Shareholders and Provides Update on Development Programs

Inhibikase Therapeutics (IKT) Issues Letter to Shareholders and Provides Update on Development Programs
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Miltonh wernerInhibikase therapeutics incInhibikase or companyInstitute of the national institutes healthDrug administration for ikNational institute of neurological diseaseInhibikase therapeuticsAbelson tyrosine kinasesFellow shareholdersDrug administrationMultiple system atrophyNational instituteNeurological diseaseNational institutesPulmonary arterial hypertension

Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs

BOSTON and ATLANTA, April 18, 2024 Inhibikase Therapeutics, Inc. , a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson s.

United statesMiltonh wernerAlex loboInhibikase or companySternir incExchange commissionInstitute of the national institutes healthNational institute of neurological diseaseCompany contactDrug administration for ikInhibikase therapeutics incAbelson tyrosine kinasesFellow shareholdersInhibikase therapeuticsDrug administrationMultiple system atrophy